BACK

news

Congratulations to HitGen for NTRK/ROS1 Inhibitor HG030 Approved for Clinical Trial

2020-04-02

Congratulations to HitGen for their small-molecule tyrosine kinase inhibitor HG030 and tablets (CXHL2000004CXHL2000003) has obtained IND approval from the CDE (Center For Drug Evaluation), NMPA for clinical trials. The potential indications for HG030 are against the solid tumors harboring NTRK1/2/3/ROS1 fusion genes.

 

Sundia assists HitGen to complete some in vitro pharmacodynamics tests, formulation research and production of HG030 tablets, which accelerated the development of HitGen's new drugs.

 

Sundia once again demonstrates our one-stop service platform is been able to shorten the timeline and reduce the cost for the development of customers' preclinical new drug programs. Sundia strive to provide a fully integrated CRO services and quality project management service for more and more partners, reducing cost and increase efficiency for the drug research and development. We are looking forward to the success of HitGen on bringing more innovative and quality drug to Chinese patients.

 

About HitGen Inc.

 

HitGen is a rapidly growing biotech company with headquarters based in Chengdu, China, with a subsidiary in the USA. HitGen has established an industry-leading platform for early-stage drug discovery research centred on DNA encoded chemical libraries (DELs). HitGen’s DELs include encoded syntheses for hundreds of billions of novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes in North America, Europe and Asia to discover and develop novel therapeutics of the future.

For more information, please call +86-28-85197385 or visit www.hitgen.com.

For media inquiries: media@hitgen.com

For investor inquiries: investors@hitgen.com

For business development: bd@hitgen.com

 

About Sundia

 

As a leading, fully-integrated ‘one-stop-shop’ service provider, Sundia provides a variety of CRO services in drug discovery and development which includes Library Design, Parallel Synthesis, Custom Synthesis, Medicinal Chemistry, in vitro & in vivo Biology, DMPK, Process Development, Analytical Chemistry, Formulation Development, and Preclinical testing to meet clients' specific project needs. Leveraging our rich project management and IND submission expertise, Sundia can efficiently integrate all the studies that are required for NMPA/FDA IND submissions and are compliant with global GMP standards.

Contact:+86(21)51098642

Email: info@sundia.com

Website: www.sundia.com

 

 

share this